Dr. Tse-Wen Chang, Chairman
Please see Founder.
Dr. Hsing-Mao Art Chu, CEO
Dr. Chu earned his bachelor’s degree from Chang Gung University, followed by a master’s degree from National Yang Ming University and a Ph.D. from National Taiwan University. He conducted postdoctoral research at the Institute of Biological Chemistry, Academia Sinica, and in 2011 joined the laboratory of Distinguished Research Fellow Dr. Tse-Wen Chang at the Genomics Research Center, focusing on antibody engineering. His research centered on elucidating the molecular mechanisms underlying the interactions between CεmX and anti-CεmX.
In 2015, Dr. Chu joined Immunwork to lead R&D efforts using the proprietary T-E technology platform, advancing multiple drug programs. He has overseen six proof-of-concept successes, with two candidates entering human clinical trials, and is a co-inventor of more than 90 related patents. In 2023, Dr. Chu was appointed CEO of T-E Meds, while concurrently serving as Vice President of R&D at Immunwork. He currently serves as CEO of T-E Pharma, continuing to lead the company’s R&D and innovation efforts and driving novel drug candidates toward clinical development and commercialization.
Ms. Ying-Rong Lai, COO
Ms. Lai holds a Master’s degree in Biotechnology Management from National Taiwan University. Throughout her career, she has gained experience across multiple industries, including internal cost control and estimation, participation in industry tenders, and business management. She also spent several years in the higher education sector and engaged in both domestic and international trade, before ultimately entering the financial and accounting sector. She has demonstrated outstanding management experience across various business domains. With over a decade of experience in the financial industry, she has received multiple performance awards during her career.
In 2014, she was invited by Dr. Tse-Wen Chang to join the company’s executive team, assisting in the establishment of Immunwork and overseeing administrative and financial planning. She currently serves as Chief Operating Officer (COO) of T-E Pharma, responsible for company operations and overall management.
Dr. Ya-Shan Chuang, Director, Medical Affairs
Dr. Chuang received his bachelor’s degree in Life Sciences from National Tsing Hua University. He subsequently conducted research at Academia Sinica, National Taiwan University Hospital, and the University of Minnesota, and earned his Ph.D. in Biochemistry, Molecular and Cell Biology from Cornell University under the mentorship of Dr. Scott Emr, a member of the U.S. National Academy of Sciences. He possesses extensive research experience in stem cells, immunology, metabolism, and membrane trafficking. Prior to joining Immunwork in 2023, Dr. Chuang served as a Project Manager at Medigen Vaccine Biologics Corporation, where he was responsible for preclinical studies of COVID-19 vaccine development and participated in clinical trial programs. His research findings have been published in leading scientific journals.
At Immunwork, Dr. Chuang currently leads the clinical planning and execution of TE-8214 (a therapeutic candidate for neuroendocrine tumors) and TE-8105 (a therapeutic candidate for weight management). He successfully completed the first-in-human clinical trials of TE-8214 and TE-8105 in Australia, demonstrating preliminary safety and efficacy, and is currently advancing both programs into Phase II clinical trials.
Dr. Wendy Mun-Teng Wong, Associate Director, Preclinical/Clinical Transition
Dr. Wong earned her Ph.D. in Molecular and Cell Biology from Universiti Sains Malaysia (USM) in 2013 and completed postdoctoral training at the Institute of Biomedical Sciences, Academia Sinica, focusing on hepatitis C virus replication mechanisms.
Since joining Immunwork in 2018, Dr. Wong served as Project Manager, leading preclinical drug development programs in metabolic diseases, including diabetes, obesity, and fatty liver disease (MASH/NASH). Her responsibilities included strategic planning and execution of critical preclinical studies. Between 2024 and 2025, she held the role of Preclinical-to-Clinical Translation Manager, where she led the integration of preclinical data to support clinical trial initiation, coordinated cross-functional development activities, and collaborated closely with regulatory teams to ensure alignment with global regulatory expectations. Dr. Wong currently serves as Preclinical/Clinical Translation Associate Director, overseeing translational strategies across preclinical and early clinical development and driving the progression of the company’s pipeline toward first-in-human studies and key clinical milestones.
Dr. Ting Chen, Senior Manager, Strategy of Product Portfolio
Dr. Chen received her Ph.D. in Bioinformatics and Structural Biology from National Tsing Hua University in 2010. She subsequently conducted postdoctoral research at National Tsing Hua University (2010–2014) and the Institute of Biomedical Sciences, Academia Sinica (2014–2021), where she focused on structural biology, biophysical research and antiviral drug development. Her research findings have been published in several international peer-reviewed journals.
Dr. Chen joined Immunwork in 2022 as Strategy of Product Portfolio Manager. She is responsible for patent management, corporate website development and maintenance, as well as government subsidy grant and award applications. She has successfully supported the company in securing multiple SBIR grants from Taiwan’s Ministry of Economic Affairs and contributed to it’s recognition with the National Innovation Award. Currently, Dr. Chen focuses on advancing the market positioning and industrial application of the company’s products and technologies, while actively enhancing media exposure and market engagement to further strengthen the company’s overall industry influence and visibility.
Dr. Jon Wright, Manager, IT and Preclinical/Clinical Studies
Dr. Jon received his bachelor’s degree in Chemistry and Biology from the University of Keele in 1992 and his Ph.D. in Chemistry and Biochemistry from the University of Essex, U.K. in 1996. Following this he took up a postdoctoral position at the Institute of Biomedical Sciences, Academia Sinica in the laboratory of Distinguished Research Fellow Dr. Carmay Lim where he researched protein-protein, protein-DNA and protein-small molecule interactions with an emphasis on complex structural modeling, dynamics and design. During his time at IBMS he operated as a researcher, lab manager and designed, built and managed the lab network environment, a high performance computing cluster and a highly available SAN system.
Dr. Jon joined Immunwork in 2022 and began peer reviewing pre-clinical study reports, documentation and managing the IT systems. Since joining the preclinic/clinic teams he has helped oversee 2 successful clinical trials and is actively involved in the design and running of the follow-up trials that are in progress. In 2025, he began implementing the IT requirements for the upcoming IPO process. Dr. Jon was appointed as Manager, IT and Preclinical/Clinical Studies in 2025.